Literature DB >> 22193839

Medical treatment of atrial fibrillation.

A John Camm1, Christian F Camm, Irina Savelieva.   

Abstract

Atrial fibrillation is an increasingly common arrhythmia which is associated with a substantial burden of cardiovascular disease. The arrhythmia is mostly treated with pharmacological therapy, although some interventional techniques such as left atrial ablation, atrioventricular nodal ablation plus pacemaker implantation, and left atrial appendage occlusion or excision are gaining popularity. The concept of primary prevention of atrial fibrillation with therapies targeting the formation and progression of atrial substrate has also recently evolved. Medical treatment is directed at either rate control (slowing the ventricular rate and allowing atrial fibrillation to continue) or rhythm control (restoring and maintaining sinus rhythm). There are different types of therapy for each purpose. Antiarrhythmic drug therapy, however, is difficult and inadequate with the agents that are now available. Treatment may be ineffective or complicated by cardiac or extracardiac adverse effects. Guidelines exist to help physicians choose appropriate therapies, but they have required and continue to need revision to cope with the rapid development and accumulating experience with new treatments. This review provides a contemporary evidence-based insight into the medical management of atrial fibrillation in the modern era.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22193839     DOI: 10.2459/JCM.0b013e32834f23e1

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  5 in total

Review 1.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 2.  Primary Prevention of Atrial Fibrillation where are we in 2012?

Authors:  Massimo Imazio
Journal:  J Atr Fibrillation       Date:  2012-08-20

3.  The HATCH and CHA2DS 2-VASc scores. Prognostic value in pulmonary vein isolation.

Authors:  E U Schmidt; R Schneider; J Lauschke; I Wendig; D Bänsch
Journal:  Herz       Date:  2013-05-18       Impact factor: 1.443

4.  Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.

Authors:  L Herrera; I Leal; F Lapi; M Schuemie; V Arcoraci; F Cipriani; E Sessa; A Vaccheri; C Piccinni; T Staniscia; A Vestri; M Di Bari; G Corrao; A Zambon; D Gregori; F Carle; M Sturkenboom; G Mazzaglia; G Trifiro
Journal:  Osteoporos Int       Date:  2015-03-10       Impact factor: 4.507

5.  Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.

Authors:  Jan Murin; Lisa Naditch-Brûlé; Sandrine Brette; Chern-En Chiang; James O'Neill; P Gabriel Steg
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.